NYSE · NUVB
Healthcare · Biotechnology
$5.80
Down-$0.14 (-2.36%)
Updated Sep 16, 2026, 4:33 AM
SID Score
5.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NUVB closed at $5.80 after 20 trading sessions, down 16.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $5.90 | $5.91 | $5.63 | $5.80 | 7.05M |
| Sep 14, 2026 | $5.90 | $6.135 | $5.77 | $5.94 | 10.03M |
| Sep 11, 2026 | $6.36 | $6.39 | $5.95 | $6.07 | 4.32M |
| Sep 10, 2026 | $6.44 | $6.45 | $6.17 | $6.28 | 7.98M |
| Sep 9, 2026 | $6.55 | $6.715 | $6.50 | $6.52 | 2.61M |
| Sep 8, 2026 | $6.69 | $6.746 | $6.58 | $6.61 | 2.54M |
| Sep 4, 2026 | $6.78 | $6.87 | $6.72 | $6.81 | 3.76M |
| Sep 3, 2026 | $7.03 | $7.1301 | $6.65 | $6.77 | 5.28M |
| Sep 2, 2026 | $6.75 | $6.97 | $6.69 | $6.93 | 5M |
| Sep 1, 2026 | $6.60 | $6.95 | $6.58 | $6.64 | 4.84M |
| Aug 31, 2026 | $6.695 | $6.7528 | $6.485 | $6.66 | 3.2M |
| Aug 28, 2026 | $6.90 | $6.9956 | $6.625 | $6.66 | 3.66M |
| Aug 27, 2026 | $6.91 | $7.18 | $6.88 | $6.99 | 3.53M |
| Aug 26, 2026 | $7.09 | $7.12 | $6.91 | $6.96 | 3.44M |
| Aug 25, 2026 | $6.93 | $7.13 | $6.855 | $7.10 | 4.15M |
| Aug 24, 2026 | $6.82 | $6.97 | $6.66 | $6.76 | 3.02M |
| Aug 21, 2026 | $6.98 | $7.09 | $6.88 | $6.93 | 6.04M |
| Aug 20, 2026 | $7.31 | $7.31 | $6.76 | $6.83 | 5.31M |
| Aug 19, 2026 | $7.16 | $7.58 | $7.02 | $7.26 | 11.55M |
| Aug 18, 2026 | $6.57 | $6.96 | $6.44 | $6.96 | 6.99M |
The latest Smart Investors Daily articles mentioning NUVB.
NUVB research
Company profile and research snapshot.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 18, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Jul 27, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 23, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Nuvation Bio Inc. (NUVB) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 9:20 AM EDTCompany ParticipantsDavid Hung - Founder, President,...
Yahoo · Sep 6, 2026
Cramer flagged the company as too risky for most people, even as the stock climbs on real medical news.
Yahoo · Sep 3, 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Yahoo · Sep 2, 2026
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats and one-on-one meetings at the following conferences:
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NUVB.
